Publikationen

 

Publikationen 2014


The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

Filipits M, Nielsen T, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Singer C, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens J, Gnant M, for the Austrian Breast and Colorectal Cancer Study Group

Published OnlineFirst February 11, 2014

Download PDF

 

Publikationen 2013


The EndoPredict score provides prognostic information on late distant metastases in ERþ/HER2 breast cancer patients

Dubsky P, Brase J C, Jakesz R, Rudas M, Singer C F, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann M C, Petry C, Weber K E, Fisch K, Kronenwett R, Gnant M, Filipits M on behalf of the Austrian Breast and Colorectal Cancer

British Journal of Cancer (2013)
Advance online publication 24 October 2013

 

Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M and Dandachi N

Modern Pathology 1-10, 2013.

 

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)..

Ann Oncol 24, 640-647, 2013.

 

Cytochrome P450 2D6 poor metabolizer phenotype is associated with worse outcomes in women receiving tamoxifen: results from the Austrian Breast and Colorectal Study 8

Goetz MP, Suman VJ, Ames MM, Gnant M, Filipits M, Hoskin TL, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ingle JN.

Clin Cancer Res 107, 1978-1986, 2013.

 

Publikationen 2003-2011


The benefit of adjuvant sequencing of tamoxifen and anastrozole over tamoxifen alone is confined in women with low proliferating endocrine-responsive breast cancer: Results from 1,587 centrally reviewed Ki67-labelling determinations in the Austrian Breast and Colorectal Cancer Study Group Trial 8

Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer C, Dietze O, Greil R, Jelen A, Böhm G, Jasarevic Z, Haid A, Gruber C, Pöstlberger S, Filipits M, Gnant M.

Clin Cancer Res 17, 7828-7834, 2011.

 

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Schwab M, Brauch H, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M.

Clin Cancer Res 17, 6012-6020, 2011.

 

Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy

Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF, for the Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res 15, 5888-5894, 2009.

 

Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy

Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M, for the Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res 14, 1767-1774, 2008.

 

Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group

Filipits M, Pohl G, Rudas M, Dietze O, Lax S, Grill R, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R.

J Clin Oncol 23, 1161-1168, 2005.

 

High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin

Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R, Filipits M.

J Clin Oncol 21, 3594-3600, 2003.